Cumberland Advisors Market Commentary.
View this email in your browser
Zika Vaccine
May 19, 2020
David R. Kotok
Chairman of the Board & Chief Investment Officer
Email | Bio

What seems like ages ago, we wrote about Zika. Multiple commentaries became a pamphlet which was and is available free. Here’s the link:


In that pamphlet is a chapter about how a political fight held up Zika vaccine research for a year. The costs in human and monetary terms are estimated in the pamphlet. Most important for me is the full condemnation of Democrats and Republicans who failed their constituents by not uniting in national purpose.


There’s some news on that front. A Zika vaccine has completed a Phase 1, 52-week human trial. It was well tolerated, required two doses, and will require boosters to maintain immunity. See “Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial,” The Lancet,


This article in The Lancet further describes the vaccine candidate and its strengths and limitations. It also summarizes the outcomes of the Zika epidemic: “Vaccine development during global epidemics: the Zika experience,” 


Have we learned anything since the Zika outbreak? Is our national response to COVID-19 improved by those lessons or were the lessons ignored?


The debate over preparedness now rages in our national politics and our media, both public and social. It will continue, and it will intensify. Here in Florida, with 29 electoral college votes at stake, the debate is already intense.


And that’s before hurricane season starts with the Gulf of Mexico at record heat, before the red tide arrives with its carriages of respiratory distress, before the scandalous Florida Department of Health data and reporting revelations are corrected, before completely universal testing and before any COVID-19 surges occur in a state reopening that packs a bar on the Sarasota main drag with folks partying, unmasked, shoulder to shoulder.


More will be revealed. Meanwhile, as the mosquito season arrives, at least there will be a Zika vaccine on the horizon, and the immunity it will confer when it is ready, though it may be short-lived, might well last long enough to prevent additional fetal infections and their devastating results.


As for COVID19, opening up too fast and too loose with minimal restrictions is risky business.  The Rt [1] is now rising in Florida; this ain’t over.

Rt is a key measure of how fast a virus is growing. It’s the average number of people who become infected by an infectious person. If Rt is above 1.0, the virus will spread quickly. When Rt is below 1.0, the virus will stop spreading. (SOURCE:

LinkedIn LinkedIn
Twitter Twitter
Website Website
Facebook Facebook
YouTube YouTube

Cumberland Advisors is a proud sponsor of the GIC's ongoing
“Analyzing Pandemics” series of Executive Briefings.

 COVID-19 and Small Business

COVID-19 and Small Business is the theme of this Executive Briefing, the eighth in our “Analyzing Pandemics” series. Attendees will gain context and perspective regarding how the economic shutdown is impacting small businesses across the U.S., insights into the Paycheck Protection Program, and a capital market outlook.

Date: Thursday, May 21, 2020 Time: 4:00 PM - 5:00 PM

Location: Virtual Event

Free Registration Here:


Holly Wade

Holly Wade

Director of Research and Policy Analysis, NFIB

Holly Wade is the director of research and policy analysis for NFIB, where she conducts original research and studies public policy effects on small businesses.

Read More

Peter Boockvar

Peter Boockvar

Chief Investment Officer, Bleakley Advisory Group

Mr. Boockvar is the Chief Investment Officer of Bleakley Advisory Group, a New Jersey based wealth management firm. He is also the Editor of The Boock Report, a macro economic and market newsletter.

Read More

Copyright © 2020 Cumberland Advisors, All rights reserved.

unsubscribe from this list    update subscription preferences